183 related articles for article (PubMed ID: 34858904)
1. Childhood Hypercalciuric Hypercalcemia With Elevated Vitamin D and Suppressed Parathyroid Hormone: Long-Term Follow Up.
Gurevich E; Levi S; Borovitz Y; Alfandary H; Ganon L; Dinour D; Davidovits M
Front Pediatr; 2021; 9():752312. PubMed ID: 34858904
[No Abstract] [Full Text] [Related]
2. Loss-of-function mutations of CYP24A1, the vitamin D 24-hydroxylase gene, cause long-standing hypercalciuric nephrolithiasis and nephrocalcinosis.
Dinour D; Beckerman P; Ganon L; Tordjman K; Eisenstein Z; Holtzman EJ
J Urol; 2013 Aug; 190(2):552-7. PubMed ID: 23470222
[TBL] [Abstract][Full Text] [Related]
3. Kidney function and influence of sunlight exposure in patients with impaired 24-hydroxylation of vitamin D due to CYP24A1 mutations.
Figueres ML; Linglart A; Bienaime F; Allain-Launay E; Roussey-Kessler G; Ryckewaert A; Kottler ML; Hourmant M
Am J Kidney Dis; 2015 Jan; 65(1):122-6. PubMed ID: 25446019
[TBL] [Abstract][Full Text] [Related]
4. Idiopathic infantile hypercalcemia in children with chronic kidney disease due to kidney hypodysplasia.
Gurevich E; Borovitz Y; Levi S; Perlman S; Landau D
Pediatr Nephrol; 2023 Apr; 38(4):1067-1073. PubMed ID: 36156733
[TBL] [Abstract][Full Text] [Related]
5. Hypervitaminosis D Secondary to a
Collins L; Boehm E; Luxford C; Clifton-Bligh R; Grill V
JBMR Plus; 2023 Sep; 7(9):e10788. PubMed ID: 37701149
[TBL] [Abstract][Full Text] [Related]
6. Fluconazole in hypercalciuric patients with increased 1,25(OH)
Bertholet-Thomas A; Portefaix A; Flammier S; Dhelens C; Subtil F; Dubourg L; Laudy V; Le Bouar M; Boussaha I; Ndiaye M; Molin A; Lemoine S; Bacchetta J
Trials; 2022 Jun; 23(1):499. PubMed ID: 35710560
[TBL] [Abstract][Full Text] [Related]
7. 1,25-(OH)2D-24 Hydroxylase (CYP24A1) Deficiency as a Cause of Nephrolithiasis.
Nesterova G; Malicdan MC; Yasuda K; Sakaki T; Vilboux T; Ciccone C; Horst R; Huang Y; Golas G; Introne W; Huizing M; Adams D; Boerkoel CF; Collins MT; Gahl WA
Clin J Am Soc Nephrol; 2013 Apr; 8(4):649-57. PubMed ID: 23293122
[TBL] [Abstract][Full Text] [Related]
8. Overlapping Phenotypes Associated With
Molin A; Lemoine S; Kaufmann M; Breton P; Nowoczyn M; Ballandonne C; Coudray N; Mittre H; Richard N; Ryckwaert A; Lavillaureix A; Jones G; Bacchetta J; Kottler ML
Front Endocrinol (Lausanne); 2021; 12():736240. PubMed ID: 34721296
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment.
Tebben PJ; Singh RJ; Kumar R
Endocr Rev; 2016 Oct; 37(5):521-547. PubMed ID: 27588937
[TBL] [Abstract][Full Text] [Related]
10. Mild Idiopathic Infantile Hypercalcemia-Part 1: Biochemical and Genetic Findings.
Lenherr-Taube N; Young EJ; Furman M; Elia Y; Assor E; Chitayat D; Uster T; Kirwin S; Robbins K; Vinette KMB; Daneman A; Marshall CR; Collins C; Thummel K; Sochett E; Levine MA
J Clin Endocrinol Metab; 2021 Sep; 106(10):2915-2937. PubMed ID: 34125233
[TBL] [Abstract][Full Text] [Related]
11. AN INFANT WITH IDIOPATHIC HYPERCALCIURIA AND NEPHROLITHIASIS ASSOCIATED WITH CYP24A1 ENZYME POLYMORPHISM: A CASE REPORT.
Trutin I; Škorić I
Acta Clin Croat; 2022 Feb; 60(3):544-547. PubMed ID: 35282483
[TBL] [Abstract][Full Text] [Related]
12. CYP24A1 loss of function: Clinical phenotype of monoallelic and biallelic mutations.
Carpenter TO
J Steroid Biochem Mol Biol; 2017 Oct; 173():337-340. PubMed ID: 28093352
[TBL] [Abstract][Full Text] [Related]
13. Calcium and bone homeostasis in heterozygous carriers of CYP24A1 mutations: A cross-sectional study.
Cools M; Goemaere S; Baetens D; Raes A; Desloovere A; Kaufman JM; De Schepper J; Jans I; Vanderschueren D; Billen J; De Baere E; Fiers T; Bouillon R
Bone; 2015 Dec; 81():89-96. PubMed ID: 26117226
[TBL] [Abstract][Full Text] [Related]
14. A novel CYP24A1 genotype associated to a clinical picture of hypercalcemia, nephrolithiasis and low bone mass.
Ferraro PM; Minucci A; Primiano A; De Paolis E; Gervasoni J; Persichilli S; Naticchia A; Capoluongo E; Gambaro G
Urolithiasis; 2017 Jun; 45(3):291-294. PubMed ID: 27639704
[TBL] [Abstract][Full Text] [Related]
15. Mild Idiopathic Infantile Hypercalcemia-Part 2: A Longitudinal Observational Study.
Lenherr-Taube N; Furman M; Assor E; Elia Y; Collins C; Thummel K; Levine MA; Sochett E
J Clin Endocrinol Metab; 2021 Sep; 106(10):2938-2948. PubMed ID: 34139759
[TBL] [Abstract][Full Text] [Related]
16. Chronic hypercalcaemia from inactivating mutations of vitamin D 24-hydroxylase (CYP24A1): implications for mineral metabolism changes in chronic renal failure.
Colussi G; Ganon L; Penco S; De Ferrari ME; Ravera F; Querques M; Primignani P; Holtzman EJ; Dinour D
Nephrol Dial Transplant; 2014 Mar; 29(3):636-43. PubMed ID: 24235083
[TBL] [Abstract][Full Text] [Related]
17. Fluconazole as a New Therapeutic Tool to Manage Patients With NPTIIc (SLC34A3) Mutation: A Case Report.
Bertholet-Thomas A; Tram N; Dubourg L; Lemoine S; Molin A; Bacchetta J
Am J Kidney Dis; 2019 Jun; 73(6):886-889. PubMed ID: 30765103
[TBL] [Abstract][Full Text] [Related]
18. Biallelic and monoallelic pathogenic variants in CYP24A1 and SLC34A1 genes cause idiopathic infantile hypercalcemia.
Wang Q; Chen JJ; Wei LY; Ding Y; Liu M; Li WJ; Su C; Gong CX
Orphanet J Rare Dis; 2024 Mar; 19(1):126. PubMed ID: 38504242
[TBL] [Abstract][Full Text] [Related]
19. 24-Hydroxylase Deficiency Due to
Azer SM; Vaughan LE; Tebben PJ; Sas DJ
J Endocr Soc; 2021 Sep; 5(9):bvab119. PubMed ID: 34337279
[TBL] [Abstract][Full Text] [Related]
20. Clinical and biochemical phenotypes of adults with monoallelic and biallelic CYP24A1 mutations: evidence of gene dose effect.
O'Keeffe DT; Tebben PJ; Kumar R; Singh RJ; Wu Y; Wermers RA
Osteoporos Int; 2016 Oct; 27(10):3121-5. PubMed ID: 27129455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
